Enforcement record · O-054
Paradigm Peptides sentencing: what the case shows about forged COAs and mislabelled products
A polished certificate did not make the seller’s claims true. The criminal case records false testing and provenance claims, unapproved drugs and SARM products that contained testosterone instead of the labelled SARM.
Paradigm Peptides owner Matthew Kawa received a 70-month US prison sentence in July 2026 after admitting the sale and illegal importation of unapproved drugs with intent to defraud or mislead.
The case involved false testing and provenance claims. CBS also reported, from court filings, that laboratory certificates had been forged. Tested SARM products contained testosterone instead of the labelled SARM.
Written by: Yianni Kiromitis, BSc (Hons) Radiography, PgC Medical Ultrasound (General Imaging), HCPC RA38415. Sources and case status checked: 11 August 2026.
Important product distinction
The US Department of Justice said many products sold as selective androgen receptor modulators, or SARMs, were testosterone. That finding should not be rewritten as “the peptide vials contained testosterone”. The business sold peptides, SARMs, HCG and other products, but the published label-test mismatch concerns the SARM products.
What the court record established
The Department of Justice record is the primary source for the pleas, sentences and business representations.
The US Attorney’s Office for the Northern District of Indiana announced the sentences on 30 July 2026. Its official release says Kawa and Jennifer Stechkober had pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud or mislead. Kawa also pleaded guilty to importing merchandise contrary to law.
The release says the Paradigm Peptides business sold peptides, SARMs, HCG and other drugs for human consumption without FDA approval. Prosecutors said the business falsely claimed that it was FDA registered or licensed, that its products were made in the United States, and that they had been tested for quality and were safe or “pharmaceutical quality”. The products were imported from Asia, including China and India, and the defendants did not have them quality tested.
| Record | Detail |
|---|---|
| Conduct period | 2019 to 2024 |
| Matthew J. Kawa | 70 months in prison, followed by one year of supervised release |
| Jennifer L. Stechkober | 16 months in prison, followed by one year of supervised release |
| Restitution | $78,317.52 |
| Money judgment | $5 million against Kawa |
| Customers | More than 54,000 customers across all 50 US states and more than 80 countries |
| Products described | Peptides, SARMs, HCG and other drugs sold for human consumption without FDA approval |
| Label mismatch | Many products advertised and labelled as SARMs contained testosterone |
These figures describe this case. They do not establish how every online seller operates.
Which claims failed, and what evidence contradicted them?
| Seller claim or presentation | Contrary evidence in the public record | Verification lesson |
|---|---|---|
| FDA registered or licensed | DOJ said those representations were false. | Check the exact regulatory database and what a registration covers. Registration is not product approval. |
| Made in the United States | DOJ said products were imported from Asia, including China and India. | A country-of-origin claim needs traceable records, not a website statement. |
| Tested for quality | DOJ said the defendants did not have the drugs quality tested. | Ask who commissioned the test, which sample was tested and whether the laboratory can confirm the report. |
| Safe or “pharmaceutical quality” | The products were unapproved drugs; the stated quality testing had not occurred. | “Pharmaceutical quality” needs a defined, applicable standard. It is not a self-awarded grade. |
| SARM named on the label | DOJ said many SARM-labelled products contained testosterone. CBS reported testosterone in all six SARM products tested by the government. | Identity and label match require an appropriate method on a traceable sample. |
| Credible laboratory paperwork | CBS reported, based on court filings, that laboratory certificates were forged. | A PDF’s appearance cannot authenticate its issuer, batch, sample or result. |
| “Research use only” presentation | CBS reported that the plea record described the wording as false because Kawa knew the products were marketed and sold for human consumption. | Conduct, claims and intended use matter. A footer cannot neutralise the rest of the presentation. |
What is established, and what is reported?
Keeping source types separate prevents a criminal sentence, a news investigation and an individual medical account from being blended into one claim.
Established through the DOJ record
The guilty pleas, offences, sentences, financial orders, false business claims, importation, lack of quality testing, scale of sales and the SARM-to-testosterone mismatch described by prosecutors.
Reported by CBS from court filings
Forged laboratory certificates and the government testing of six SARM products. These details fit the broader fraud record, but we attribute them to CBS rather than presenting them as text from the sentencing release.
Reported individual account
CBS and the BBC reported on a customer who said he suffered a severe psychiatric episode after using a product. The sentencing release says customers reported serious physical and psychological effects, but it does not establish the clinical cause of every individual event.
This article does not diagnose that person or use one account to infer the composition of every product.
Why a certificate of analysis is not enough
A certificate is a document. It is not the sample, laboratory, chain of custody or method.
- Issuer: Is the named laboratory real, and can it confirm that it issued the report?
- Batch: Does the document identify the same batch or lot as the product in hand?
- Sample provenance: Who selected, handled and sent the sample?
- Method and measurand: Did the test measure identity, quantity, purity, sterility, endotoxin or something else?
- Result limits: What remains unknown after the reported result?
The peptide COA red-flag guide covers document authentication. The test-scope matrix explains why a purity result cannot prove sterility, safety or clinical benefit. Even a genuine report may apply only to the submitted sample.
The Paradigm case adds a direct reason to perform the first check. If the laboratory cannot verify that it issued the report, there is no reason to interpret the number printed on it.
Laboratory-document experience
From our laboratory-document review work
Eleni Kiromitis, the site’s scientific reviewer, has experience commissioning laboratory tests and reviewing certificates and chromatograms. That experience informs a simple editorial rule: we do not let a polished report stand in for verified provenance.
When we review a certificate, we separate four layers. The label states what the seller claims. The certificate states what the document reports. An independent test states what a laboratory measured in a particular sample. Scientific evidence addresses whether a defined intervention changes a defined outcome in a defined population. A result in one layer cannot silently answer a question from another.
For a document claim, we look for the issuing laboratory, report date, sample or batch reference, analytical method, stated measurand and a route to confirm issuance. For a test claim, we ask who obtained and submitted the sample, what the laboratory’s accredited scope covers and what the method cannot establish. These checks do not prove that every unexamined vial matches the tested sample.
We did not commission testing of a Paradigm Peptides product and did not review the underlying laboratory files in this case. Our account of the certificates is based on CBS’s reporting of the court filings. The case is a worked example of why verification is necessary, not an independent re-test by this publication.
Why “research use only” was not a shield in this case
CBS reported that Kawa admitted the “research use only” description was false because he knew the products were being promoted and sold for human consumption. The point is case-specific: investigators and the court record looked at conduct and presentation, not one disclaimer in isolation.
UK law is different from US federal law, but the same reading discipline helps. A product’s intended use can be assessed from its claims, presentation and function. The phrase does not grant a UK marketing authorisation or make human-use claims disappear.
Read what “research use only” means on a peptide product in the UK context.
This case should not be used to claim that every research supplier commits fraud. It shows why a seller’s own description cannot be the only evidence used to classify the product or trust its quality claims.
If you may have taken a mislabelled product
Do not use a news article or a COA to diagnose symptoms. If you feel unwell after taking any bodybuilding, peptide or hormone-related product, seek medical advice and tell the clinician what you took, when you took it and where it came from.
In the UK, use NHS 111 for urgent advice and 999 or A&E for a medical emergency.
Keep the product, packaging, batch information, order record and any certificate if it is safe to do so. Do not send medicines or personal medical information to this publication.
Frequently asked questions
What was Matthew Kawa sentenced for?
Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud or mislead and to importing merchandise contrary to law. He received 70 months in prison and one year of supervised release.
Was Jennifer Stechkober also sentenced?
Yes. The DOJ record says she received 16 months in prison followed by one year of supervised release after pleading guilty to introducing unapproved new drugs with intent to defraud or mislead.
Did Paradigm Peptides forge COAs?
CBS reported, based on court filings, that Kawa and Stechkober forged laboratory certificates. The DOJ release separately records false quality-testing claims and says the drugs were not quality tested.
Did investigators find testosterone in peptide products?
The cited public sources say SARM-labelled products contained testosterone. They do not support rewriting the finding as “peptide products contained testosterone”.
Does a genuine COA prove a product is safe?
No. A genuine certificate can report a result for a specific sample and method. It does not by itself prove batch match, sterility, safety, effectiveness or that every vial is equivalent.
Does “research use only” make a product legal to sell for human use?
Not by itself. A disclaimer cannot grant an authorisation or erase human-use claims elsewhere. The operative legal test depends on the jurisdiction and the product’s full presentation and function.
Does this case prove every online peptide seller is fraudulent?
No. It establishes the offences admitted and facts recorded in this case. It also demonstrates why seller claims, certificates and labels need independent verification.
Sources checked on 11 August 2026
Primary court and regulator records lead. News investigations are clearly attributed where they add details not stated in the DOJ release.
| Source | Type | Use |
|---|---|---|
| US Department of Justice sentencing release, 30 July 2026 | Primary | Pleas, sentences, financial orders, business claims, sales scale and SARM mismatch. |
| United States v. Matthew Kawa case page | Primary | Case status, victim route and final hearing record, updated 3 August 2026. |
| CBS News investigation, 30 July 2026 | Secondary reporting | Forged-certificate and six tested-SARM details attributed to court filings. |
| BBC News investigation | Secondary reporting | Reported individual experience and wider consumer context. |
| FDA bodybuilding-product warning | Primary regulator | Hidden-steroid risk and the need for clinical advice. |
| MHRA suspicious online seller service | Primary UK | Seller-reporting route and the information requested. |
| MHRA Yellow Card route | Primary UK | Suspected medicine reaction and product-problem reporting. |